LIFE SCIENCE LIVE 2019

Artificial Intelligence & Health –

May 15–16, Turku Fair and Congress Center

 

Preliminary Programme

MEMBERS OF THE LIFE SCIENCE LIVE PROGRAMME COMMITTEE

Wednesdays speakers

Thurdays speakers

SPEAKER BIOS

 08:15 Registration
 09:00 - 10:00 Auditorium Common Plenary for all Life Science Live Tracks: AI Imperatives for a Changing World

Plenary. IBM: Andrew Fried, IBM Global Life Sciences Industry Leader

 10:00 - 10:30 Coffee break
 10:10 Sponsor Stage Sensitive diagnostic instrumentation for photon-upconverting coupled nanoparticles

Ida Erling, Labrox Founder & CEO, Labrox Oy

 10:30 - 11:45 Conference Room 3 The Science Track: Session 1 – Intelligent Solutions for Health

Part One of Session One. Confirmed Speakers:

Professor Moncef Grabbouj, University of Tampere
Real-Time Patient-Specific ECG Classification by Convolutional Neural Networks

In this talk, we shall discuss how we approach AI from a signal processing, pattern recognition and machine learning point of view to solve pertinent problems in many areas, including biomedical signal processing. We present a hierarchical layered approach that exploits different types of sensor and non-sensor signals and design suitable representation, processing and analysis algorithms in order to apply machine learning, including deep and shallow learning. We shall then exploit the layered approach in a wide array of applications, with specific emphasis on ECG classification, where we shall present a fast and accurate patient-specific electrocardiogram (ECG) classification and monitoring system. The proposed system uses an adaptive implementation of 1D Convolutional Neural Networks (CNNs) which is used to fuse the two major blocks of the ECG classification into a single learning body: feature extraction and classification. For each patient, an individual and simple CNN will be trained using a relatively short segment of patient ECG training data. The proposed solution can be used for real-time ECG monitoring and early alert system on a light-weight wearable device. We will also show that the network can be used to classify possibly long ECG data accurately. The results over the MIT-BIH arrhythmia benchmark database demonstrate that the proposed solution achieves a superior classification compared to the state-of-the-art methods for the detection of ventricular ectopic beats (VEB) and supraventricular ectopic beats (SVEB).

 

Professor Martin Cowie, Imperial College London
Learning lessons the hard way in remote monitoring of complex cardiac disease

 10:30 - 11:45 Auditorium HealthBIO Seminar – Session 1

10.30   Opening words by the Chair of the day. Jari Forsström, Abomics Oy and Healthtech Finland, Genomic Industry SIG
10.45   Finnish biotech year 2018. Tero Piispanen, HealthTurku, Turku Science Park Oy
11.15   Are there any more traditional Venture Capitalists? Walter Stockinger, Hadean Ventures
11.45   Lunch

 10:30 - 11:45 Banquet hall i-HD: Session 1 – Getting the best value from health data – a multi-stakeholder prespective

Speakers:

Evidencing value based care through hospital EHRs and ICHOM standards: Thomas Allvin, EFPIA
The hospital perspective: Juuso Blomster, University of Turku
The pharma industry perspective: Bart Vannieuwenhuyse, Janssen
The patient perspective: Peter van Galen, Belgium, Patient representative

Panel discussion

 11:45 - 13:15 Lunch and Exhibition
 12:15 Sponsor Stage From one-size-fits-all medicine to more personalized medicine

Sammeli Liikkanen, Chief digital officer, Orion Corporation, Orion PharmaOrion

 12:35 Sponsor Stage Real World Data in Scientific Research and Innovation

Arho Virkki, Adjuct Professor of Medical Mathematics at University of Turku, Head of Auria Clinical Informatics

 12:51 Sponsor Stage Bayer in Finland: We employ, invest and research

Peter Essen, Bayer

 13:15 - 13:45 Auditorium How digital technologies will change the business

Kristoffer Miving, Digital lead, Nordics & Baltics, Janssen

 13:45 - 14:15 Auditorium From laboratory to data, and from data to clinical value

Tommi Lehtonen, CEO, Blueprint Genetics Oy

 14:15 - 14:45 Auditorium Advancing personalized medicine from drug discovery through diagnosis

Lee Tien, Technology & Innovation Manager, PerkinElmer Inc.

 14:45 - 15:15 Coffee and Exhibition
 14:50 Sponsor Stage Fair Data economy drives towards real world evidence

Ilkka Räsänen, Leading Expert, Sitra

 15:15 - 16:30 Conference Room 3 The Science Track: Session 1 – Intelligent Solutions for Health

Part Two of Session One. Confirmed Speakers:

Professor Ion Petre, University of Turku
Network Controllability: Algorithmics for precision cancer medicine:

Jason Swedlow,Centre for Gene Regulation & Expression, University of Dundee, UK, Glencoe Software Inc., Seattle, WA
OME’s Bio-Formats, OMERO, & IDR: Open Tools for Accessing, Integrating, Mining and Publishing Image Data @ Scale

 15:15 - 16:30 Banquet hall i-HD: Session 2 – Essential enablers for scaling up the value of health data

Speakers

Measuring and improving data quality in hospitals:
Professor Pascal Coorevits, i~HD and University of Gent
Frank Staelens, OLV Hospital Aalst, Belgium

Complying with the GDPR when reusing real world data for research:
Dr Nathan Lea, i~HD and University College London
Saara Malkamäki, SITRA

Dr Filip De Meyer, i~HD and University of Gent

Panel discussion

 15:15 - 16:30 Auditorium HealthBIO Seminar – Session 2

15.15   The New Modalities Ecosystem project ; what is there for me? Antti Haapalinna, Orion Pharma Ltd
15.40   Creating Companies of Scale. Giles Dudley, Senior Business Developer, BioInnovation Institute (Novo Foundation)
16.05   How Business Finland can help drive innovation and international growth in Life Sciences. Helena Viita, PhD, Chief Advisor, SME & Midcap, Health & Wellbeing, Business Finland
16.20   Ending discussion. Jari Forsström, Business Finland

 19:00 Restaurant Festo, Turku Fair Center Get together -evening event
 09:00 - 09:40 Auditorium Plenary keynote lecture with i-HD – Professor Dipak Kalra, President of i~HD

Dipak Kalra, President of the European Institute for Innovation through Health Data

 09:40 - 11:00 Conference Room 3 The Science Track: Session 2 – Data to knowledge for better public and individual health

Part One of Session Two

Confirmed Speakers:

Professor Olli Raitakari, University of Turku
Epigenetic inheritance of disease risk – implications for public health

Dr. Laura Elo, University of Turku
Transforming data to knowledge for better healthcare:
The rapid developments in modern biotechnology have enabled large-scale measurements of molecular events in health and disease. This has opened up new possibilities to improve clinical decision making and drug development. However, data alone are not enough but effective computational methods and models are needed. The focus of this talk is on computational approaches that enable robust and reproducible interpretation of the large-scale molecular as well as clinical data. The ultimate goal is to improve the diagnosis, prognosis and treatment of complex diseases, such as diabetes and cancer.

 

 

 09:40 - 11:00 Banquet hall i-HD: Session 3 – Innovative projects making great use of health data

Opening remarks, Professor Dipak Kalra, President of i~HD

EHR2EDC, Nadir Ammour, Sanofi
EHDEN, Nigel Hughes, Janssen
Trillium II and the International Patient Summary, Catherine Chronaki, HL7 Europe
Digital Health Europe, Oliver Zobell, Scientific Officer eHealth, Jülich

 09:40 - 11:00 Auditorium 2 HealthBIO Partnering – Session 1

Registration to Partnering on May 16th from this link.

Register for one-on-one partnering sessions

 09:45 - 11:15 Conference Room 1-2 UK-Nordic Public-Private partnering in AI as enabler for HealthTech

UK Department for International Trade (British Embassy Helsinki) and The Science & Innovation Network in collaboration with Scottish Development International and Turku University of Applied Sciences welcome you to discover how the UK triple helix of academia, industry and government utilises artificial intelligence as enabler in the health technology space.

The keynote speakers representing the following organisations to be announced and the final programme published closer to the date.

  • The Alan Turing Institute – UK national institute for data science and AI
  • UK Medicines Discovery Catapult
  • iCAIRD (The Industrial Centre for Artificial Intelligence Research in Digital Diagnostics)

Please join the discussion and come to network with like-minded professionals. Registration to the event closes on Monday 6 May. Please, register here

For any queries, please don’t hesitate to contact the organiser.

.

 11:00 - 13:00 Lunch and Exhibition
 11:00 - 13:00 Turku Fair Center Restaurant Pitching competition hosted by Business Finland
Dr. Leona Gilbert, Ph.D. / Te?ted Oy
Te?ted is revolutionizing the way tick-borne disease are diagnosed at a 90% cost reduction for the patient. 80 countries all over the globe are reporting people suffering from tick-borne diseases and WHO has indicated that this is only going to increase. Our team is committed to get the patient tested so they can be treated and recovery quicker.  
Harri Sihto, PhD / Sartar Therapeutics
Sartar Therapeutics is a pre-clinical stage company that develops a personalized medicine treatment for gastrointestinal stromal tumor (GIST). The therapy innovation is based on discovery of novel therapy targets in GIST and repurposing and reformulation of an old drug, anagrelide.
BW Sergey Sadov / Health Samurai Finland Oy 
The description of our company was added to the webpages of the Partnering Day event previously
Anni Mörö, PhD, MSc(Tech) / Eye group, Tampere University
Eye group from Tampere University combines stem cell based tools and functional biomaterials towards innovative therapies for the benefit of the patients. Our multidisciplinary team tackles blindness by developing novel stem cell based solutions for the corneal and retinal repair through cell transplantation. We have considerable experience in human pluripotent stem cells, ocular cells and biomaterials resulting in over 100 publications and 8 patent applications.
Tejesvi Mysore / Chain Antimicrobials Oy
Chain Antimicrobials is a Biotech company focusing on developing antimicrobial coated medical devices to prevent hospital-acquired infections. Our lead product, the peptide-coated urinary catheters (PAC) have generated positive results from the in-vitro studies and currently in the preclinical study phase. PAC will improve the quality of life of patients, reduces the severity of UTIs, the financial burden on patients/healthcare provider and no extra days in the hospitals.
Preethy Paul / Team Name:  Anison, Abo Akademi University
Anison has developed an herbal ointment to remove warts, caused by Human papilloma virus (HPV).  Currently available wart treatments are not totally effective and do not treat the HPV infection. The project is in the development phase and a start-up is planned to be established in the near future.
Sakari Lätti, Head of Software Development / Aurlide ltd
Aurlide ltd is specialised in computer-dependent drug discovery, with special interest in identification of protein-protein interaction (PPI) modulators and their hit-to-lead optimisation. Our technology is unique and enables conversion of undruggable PPIs to druggable – technique that is only available via us.
Wlodek Laskowski, Board Member, CFO / Cardiolyse Oy
Cardiolyse is an algorithm-powered cloud platform that collects and analyses any EСG device and leads-number data to provide personal EСG baseline heart health reports and deliver up to 2 months data-based predictions on dangerous heart events to timely prevent them.
The clear analytic summary of remote heart health monitoring indicates the autonomous nervous system status and accounts user’s HRV, temperature and lifestyle factors to help the high risk groups, like diabetes or elderly people, to forecast the rising dangerous heart events and make them preventable.
Invitation to pitching competition hosted by Business Finland
 13:00 - 14:00 Conference Room 3 The Science Track: Session 2 – Data to knowledge for better public and individual health

Part Two of Session Two

Confirmed Speakers:

Dr. Antti Karlsson, Auria Biobank
Huge amounts of tissue samples and related patient information are gathered in biobanks. This combined with modern research tools and computing power creates vast amounts of possibilities. Using clear examples, I will shortly introduce different research projects we have done ranging from ordinary retrospective register studies all the way to using artificial intelligence in the analysis of patient dictations and histopathological images

Antti Kangas, CTO & Co-Founder, Nightingale Health Ltd

 13:00 - 14:00 Banquet hall i-HD: Session 4 – Secondary use of clinical data in Finland, implementing a new law

Chair: Dipak Kalra

Petri Virolainen,Hospital Director of Turku University Hospital. Chief Medical Officer

Use of pharmacogenetic data in connection with personalized pharmaceutical treatment: Jari Forström, Turku University Hospital and Abomics Ltd

 

 

 13:00 - 16:00 Auditorium 2 HealthBIO Partnering – Session 2

Registration to Partnering on May 16th from this link.

Register for one-on-one partnering sessions

 14:00 - 18:00 Public Exhibition
 14:10 Sponsor Stage How Business Finland can help drive innovation and international growth in Life Sciences

Sampo Sammalisto, Ph.D. Program manager, Personalised Health, Health & Wellbeing, Business Finland

 14:30 Sponsor Stage Uudistuuko sikiöseulonta?

PerkinElmer

 14:50 Sponsor Stage Biolääketieteen opiskelijaksi Turun yliopistoon?

Haastateltavana opiskelija Mona Halme.

 15:00 Sponsor Stage Ruoka on moniaistinen päivän piriste

Haastateltavana apulaisprofessori Mari Sandell Turun yliopiston funktionaalisten elintarvikkeiden kehittämiskeskuksesta

 15:15 Sponsor Stage Ajankohtaista Lymen borrelioosista

Haastateltavana bakteeriopin apulaisprofessori Jukka Hytönen Turun yliopistosta

 15:30 Sponsor Stage Edistä tiedettä ja luovuta näytteesi biopankkiin

Haastateltavana Auria Biopankin kehityspäällikkö Antti Karlsson